NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

I found the ARGOS prospectus for their IPO from February 12, 2014.

http://www.sec.gov/Archives/edgar/data/1105533/000119312514040941/d621316d424b4.htm


Initial thoughts:

1. They are behind DCVAX phase 3 trial by about a year.

2. AGS-003 treats Kidney Cancer, but both AGS-003 and DC-VAX appear to be capable of treating most or all solid tumor cancers.

3. They do not have the equivalent of DCVAX-Direct, so they may start a phase 2 trial for AGS-003 on various solid tumor cancers. Their lack of DCVAX-Direct like platform could create problems. There is nothing yet on clinical trials.gov related to a multiple tumor trial for AGS-003.

4. They do not seem to be close to the manufacturing advancements and certifications throughout the world that NWBO has.

5. One good similarity is that ARGOS is seeing that same 80% response rate from dendritic therapy.

6. Despite the NIH grant, it appears they do not have orphan status yet, which would otherwise extend their older patents. However, like IMUC, they could probably get orphan status.